# Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

> **NCT06160752** · PHASE1 · RECRUITING · sponsor: **Tyra Biosciences, Inc** · enrollment: 40 (estimated)

## Conditions studied

- Locally Advanced Cholangiocarcinoma
- Intrahepatic Cholangiocarcinoma
- Solid Tumor
- Metastatic Cholangiocarcinoma

## Interventions

- **DRUG:** Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
- **DRUG:** Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles

## Key facts

- **NCT ID:** NCT06160752
- **Lead sponsor:** Tyra Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-22
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06160752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06160752, "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06160752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*